GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Phase 2 Completed 20 enrolled Washington University School of Medicine National Comprehensive Cancer Network · collab

NaSingle-groupOpen-labelTreatment

Summary

This phase II trial studies how trametinib effects tumor cells in patients with oral cavity squamous cell carcinoma that can be removed by surgery. Trametinib may shrink the tumor by blocking an enzyme pathway needed for cell growth.

Timeline

Start: 2013-02
Primary completion: 2015-06
Completion: 2015-12

Publications

Background Judd NP, Winkler AE, Murillo-Sauca O, Brotman JJ, Law JH, Lewis JS Jr, Dunn GP, Bui JD, Sunwoo JB, Uppaluri R. ERK1/2 regulation of CD44 modulates oral cancer aggressiveness. Cancer Res. 2012 Jan 1;72(1):365-74. doi: 10.1158/0008-5472.CAN-11-1831. Epub 2011 Nov 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Trametinib	Small molecule	2 mg	Oral

GSK1120212 in Surgically Resectable Oral Cavity Squamous Cell Cancer

Summary

Timeline

Publications

Drugs

Indications